Ironwood Pharmaceuticals/$IRWD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Ticker
$IRWD
Sector
Primary listing
Employees
100
Headquarters
Website
IRWD Metrics
BasicAdvanced
$530M
21.90
$0.15
0.19
-
Price and volume
Market cap
$530M
Beta
0.19
52-week high
$5.78
52-week low
$0.53
Average daily volume
3.2M
Financial strength
Current ratio
1.132
Quick ratio
1.083
Long term debt to equity
-150.809
Total debt to equity
-228.312
Interest coverage (TTM)
3.63%
Profitability
EBITDA (TTM)
120.847
Gross margin (TTM)
67.88%
Net profit margin (TTM)
8.11%
Operating margin (TTM)
40.10%
Effective tax rate (TTM)
65.70%
Revenue per employee (TTM)
$2,960,000
Management effectiveness
Return on assets (TTM)
19.88%
Return on equity (TTM)
-8.53%
Valuation
Price to earnings (TTM)
21.901
Price to revenue (TTM)
1.776
Price to book
-2.02
Price to tangible book (TTM)
-2.01
Price to free cash flow (TTM)
4.141
Free cash flow yield (TTM)
24.15%
Free cash flow per share (TTM)
0.785
Growth
Revenue change (TTM)
-15.73%
Earnings per share change (TTM)
2,583.00%
3-year revenue growth (CAGR)
-10.32%
10-year revenue growth (CAGR)
7.07%
3-year earnings per share growth (CAGR)
-46.40%
10-year earnings per share growth (CAGR)
-17.40%
What the Analysts think about IRWD
Analyst ratings (Buy, Hold, Sell) for Ironwood Pharmaceuticals stock.
IRWD Financial Performance
Revenues and expenses
IRWD Earnings Performance
Company profitability
IRWD News
AllArticlesVideos
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Business Wire·2 weeks ago
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
Business Wire·3 weeks ago
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ironwood Pharmaceuticals stock?
Ironwood Pharmaceuticals (IRWD) has a market cap of $530M as of March 18, 2026.
What is the P/E ratio for Ironwood Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ironwood Pharmaceuticals (IRWD) stock is 21.9 as of March 18, 2026.
Does Ironwood Pharmaceuticals stock pay dividends?
No, Ironwood Pharmaceuticals (IRWD) stock does not pay dividends to its shareholders as of March 18, 2026.
When is the next Ironwood Pharmaceuticals dividend payment date?
Ironwood Pharmaceuticals (IRWD) stock does not pay dividends to its shareholders.
What is the beta indicator for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals (IRWD) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.